Journals / Uluslararası Hematoloji-Onkoloji Dergisi / 2015 / Cilt: 25 - Sayı: 3

Palyatif Torasik Radyoterapi Uygulanan Küçük Hücreli Dişi Akciğer Kanseri Hastalarinda Adaptif Tedavinin Dozimetrik Değerlendirmesi

Dosimetric Evaluation of Adaptive Therapy in Non-Small Cell Lung Cancer Patients Undergoing Palliative Thoracic Radiotherapy

Pages
178–185
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The clinical implications of this approach to CTS plan assessment should be examined using prospective studies with adequate number of patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:This study aimed to describe changes in gross tumour volume (GTV) that occurred during the course of radiotherapy (RT) in patients who underwent palliative thoracic radiotherapy (PTR), and to describe the role of adaptive treatment for protection of normal tissue.
📊
Key Findings & Data:Twenty patients with non-small cell lung cancer (NSCLC) referred for PTR were treated using a total of 10 fractions and a dose of 300 cGy/day in accordance with the initial GTV, clinical target volume (CTV), and planning target volume (PTV).
💡
Conclusion & Impact:The clinical implications of this approach to CTS plan assessment should be examined using prospective studies with adequate number of patients.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

This study aimed to describe changes in gross tumour volume (GTV) that occurred during the course of radiotherapy (RT) in patients who underwent palliative thoracic radiotherapy (PTR), and to describe the role of adaptive treatment for protection of normal tissue. Twenty patients with non-small cell lung cancer (NSCLC) referred for PTR were treated using a total of 10 fractions and a dose of 300 cGy/day in accordance with the initial GTV, clinical target volume (CTV), and planning target volume (PTV). Computed tomography simulation (CTS) images were retaken for each patient at the end of the fifth fraction, and the second plan was created. The fractional volume reduction (FVR) of the GTV and the PTV were then calculated. The changes in normal tissue dose-volume histogram (DVH) parameters between the two plans were compared. Mean GTV and PTV values were 223.9 cc and 1113.3 cc for the first plan and 196.2 cc and 1029.7 cc for the second plan , respectively. After five fractionated treatments, the FVR was 15.9% of the GTV (p < 0.001) and 8% of the PTV (p< 0.001). The daily regression for GTV was 3.1 percent. A statistically non-significant decrease occurred for the normal tissue doses. The geometric changes in GTV and PTV positively influenced the DVH parameters, but were not statistically significant. The clinical implications of this approach to CTS plan assessment should be examined using prospective studies with adequate number of patients.

Özet

Bu çalışmada palyatif torasik radyoterapi uygulanan hastalarda radyoterapi süresince gözlenen görüntülenebilir tümör hacim (GTV) değişikliklerini ve normal doku korumadaki rolünü göstermek amaçlanmıştır. Palyatif torasik radyoterapi planlanan küçük hücreli dışı akciğer kanseri (KHDAK) tanılı 20 hasta, başlangıçtaki GTV, klinik hedef hacim (CTV) ve planlanan tedavi hacmine (PTV) göre yapılan planlama ile 300 cGy/gün ile toplam 10 fraksiyonda tedavi edilmiştir. Beşinci fraksiyon sonunda hastaların bilgisayarlı tomografi simülatör (BTS) görüntüleri tekrarlanmış ve yeniden GTV, CTV, PTV ve normal dokular tanımlanarak ikinci planlamalar yapılmıştır. Beşinci fraksiyondaki GTV ve PTV’ de fraksiyone hacim azalması (FHA) hesaplanmış ve her iki planlama arasında normal doku doz-hacim histogramı (DVH) parametrelerindeki değişimler incelenmiştir. İlk planda ortalama GTV ve PTV değerleri sırasıyla 223.9cc ve 1113.3cc, 2. planda ise sırasıyla 196.2cc ve 1029.7cc olarak bulunmuştur. Beş fraksiyon tedavi sonrasında GTV’ de FHA %15.9 (p< 0.001), PTV’ de ise %8 (p< 0.001) olarak hesaplanmış, GTV için günlük regresyon oranı %3.1 olarak bulunmuştur. Normal dokuların dozları incelendiğinde ortalama kalp, özefagus, akciğer ve maksimum medulla spinalis dozlarında istatistiksel anlamlılığa ulaşmayan azalma tespit edilmiştir. Bu çalışmada radyoterapi süresince tekrarlanan BTS görüntülerinde GTV ve PTV’ de gözlenen geometrik değişiklikler DVH parametrelerini olumlu yönde etkilemiş olmasına rağmen istatistiksel anlamlı düzeye ulaşamamıştır. BTS planlamaları üzerinden yapılan bu değerlendirmemizin klinik yansımalarının prospektif ve daha fazla hasta sayılı çalışmalarla yapılmasına ihtiyaç vardır.

🔖

Cite This Article

DUMAN, E., CECEN, Y., SINDIR, B., OZDEMIR, B., YILDIRIM, M., CECEN, S., PEHLİVAN, B., YAVUZ, M. N. (2015). Palyatif Torasik Radyoterapi Uygulanan Küçük Hücreli Dişi Akciğer Kanseri Hastalarinda Adaptif Tedavinin Dozimetrik Değerlendirmesi. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 25 - Sayı: 3, 178–185. https://ajindex.com/articles/323155

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Halperin EC, Perez CA, Brady LW, Principles and Practice of Radiation Oncology 6th Edition.
  2. Philadelphia, Lippincott Williams & Wilkins, 2013: 939-973.
  3. Fournel P, Robinet G, Thomas P, et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d’Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol 23: 5910-5917, 2005.
  4. Bleehen NM, Girling DJ, Fayers PM, et al. Medical Research Council Lung Cancer Working Party. Inoperabl non-small-cell lung cancer (NSCLC): a Medical Research Council randomised trial of palliative radiotherapy with two fractions or ten fractions. Br J Cancer 63: 265-270, 1991.
  5. Bleehen NM, Girling DJ, Machin D, et al. Medical Research Council Lung Cancer Working Party. A Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance status. Br J Cancer 1992; 65: 934-41.
  6. Sundstrom S, Bremnes R, Aasebo U, et al. Hypofractionated palliative radiotherapy (17Gy per 2 fractions) in advanced nonsmall cell lung carcinoma is comparable to Standard fractionation for symptom control and survival: a national phase III trial. J Clin Oncol 22: 801-10, 2004.
  7. Lester JF, MacBeth F, Toy E, Coles B. Palliative radiotherapy regimens for non-small cell lung cancer. Cochrane Database Syst Rev 1:1, 2009.
  8. Rodrigues G, Videtic G, Sur R, et al. Palliative thoracic radiotherapy in lung cancer: An American Society for Radiation Oncology evidence-based clinical practice guideline. Practi Radiat Oncol 1: 60-71, 2011.
  9. Guckenberger M, Richter A, Wilbert J, et al. Adaptive radiotherapy for locally advanced non-small-cell lung cancer does not underdose the microscopic disease and has the potential to increase tumor control. Int J Radiat Oncol Biol Phys 81: e275 - e282, 2011.
  10. Kupelian PA, Ramsey C, Meeks SL, et al. Serial megavoltage CT imaging during external beam radiotherapy for non-smallcell lung cancer: observations on tumor regression during treatment. Int J Radiat Oncol Biol Phys 63: 1024-1028, 2005.
  11. Yan D, Vicini F, Wong J, et al. Adaptive radiation therapy. Phys Med Biol 42: 123-132, 1997.
  12. Ramsey CR, Langen KM, Kupelian PA, et al. A technique for adaptive image-guided helical tomotherapy for lung cancer. Int J Radiat Oncol Biol Phys 64: 1237-1244, 2006.
  13. Erridge SC. Gaze MN, Pri